Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data

Area of Science:

• Infectious Diseases
• Pharmacology
• Microbiology

Background:

• Multidrug-resistant Gram-negative bacteria (MDR-GNB), particularly carbapenem-resistant strains, pose a significant therapeutic challenge due to limited treatment options.
• Cefiderocol, a novel siderophore cephalosporin, has gained regulatory approval and exhibits in vitro activity against key MDR-GNB, including carbapenem-resistant *Acinetobacter baumannii* and metallo-β-lactamase producers.

Purpose of the Study:

• To review emerging clinical data on cefiderocol for treating MDR-GNB infections.
• To evaluate the translation of in vitro activity into clinical practice.
• To define cefiderocol's role in empirical and targeted therapy for MDR-GNB.

Main Methods:

• Narrative review of pivotal randomized controlled trials (RCTs).
• Analysis of initial real-world data and post-marketing experiences.
• Assessment of cefiderocol's efficacy and safety against MDR-GNB.

Main Results:

• Cefiderocol demonstrates in vitro activity against challenging MDR-GNB pathogens.
• Clinical data from RCTs and real-world studies are emerging to support its use.
• Further data are needed to fully delineate its therapeutic niche.

Conclusions:

• Cefiderocol represents a potential new option for managing difficult-to-treat MDR-GNB infections.
• Integrating RCT and real-life data is crucial for optimizing cefiderocol's clinical application.
• Continued research will clarify cefiderocol's role in combating antimicrobial resistance.